🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Thyrocare Technologies Limited THYROCARE NSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.thyrocare.com
Company Profile ↓
₹576.15
+30.38% 1Y
Mkt Cap₹9,170.31 Cr
P/E56.41
P/B16.40
Div. Yield2.73%
52W High₹649.35
52W Low₹345.06
Book Value₹36.79
EPS (TTM)₹10.21

Company Overview

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 27.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 33.8%.

Consistent Profit Growth

Net profit has compounded at 36.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.7% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 19.8%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Recent Developments

  • Mar 2026 Revenue of ₹821.89 Cr (+20.7% YoY); net profit ₹163.04 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +20.7%, earnings +78.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.7%, profit CAGR 36.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.69%
1 Year:20.74%

Compounded Profit Growth

5 Years:36.23%
1 Year:78.17%

Stock Price Performance

1 Year:+30.38%
6 Months:+57.81%
3 Months:+6.52%
1 Month:-3.66%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 76% of range
₹345.06 ₹649.35
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)46.85 · Neutral
Price Performance
1M-3.66%
3M+6.52%
6M+57.81%
1Y+30.38%
Valuation vs Sector

P/E of 56.41 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 27.9%.
  • Healthy ROCE of 33.8%.
  • Compounding revenue at 16.7% over 5 years.
  • Profit CAGR of 36.2% over 5 years.
  • Attractive dividend yield of 2.73%.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 56.4.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
56.41
Industry PE
41.64
Forward P/E
36.32
PEG Ratio
-
Book Value
₹36.79
Price to Book
16.40
P/S
10.96
EV/EBITDA
36.21
Dividend Yield
2.73%

Growth (CAGR)

Revenue 5Y
16.69%
Profit 5Y
36.23%
Revenue (YoY)
20.74%
Earnings (YoY)
78.17%

Profitability & Returns

ROCE
33.84%
ROE
27.85%
ROA
21.82%
Profit Margin
19.84%
Op Margin
24.90%
Gross Margin
73.28%
EPS (Latest Qtr)
₹3.22
EPS (TTM)
₹10.21

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
2.95
Current Ratio
3.39
Debt
₹50.69 Cr
Total Assets
₹747.22 Cr
Current Assets
₹372.29 Cr
Working Capital
₹262.38 Cr

Ownership

Promoter Holding
51.18%
Chg in Prom Hold
-9.91%
FII / Inst Holding
20.20%
Chg in FII Hold
-2.29%

Financial Snapshot

Enterprise Value
₹9,170.31 Cr
Total Revenue (TTM)
₹821.89 Cr
EBITDA
₹274.26 Cr
Free Cash Flow
₹192.36 Cr
Operating Cash Flow
₹213.24 Cr
Shares Outstanding
₹15.92 Cr
Gross Margin
73.28%
Payout Ratio
148.04%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 THYROCARE Thyrocare Technologies Limited NSEPHARMA 576.15 56.41 ₹9,170.31 Cr 2.73% 33.84% 27.85% 16.69% 36.23%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 136.00 Cr135.00 Cr148.00 Cr135.00 Cr154.00 Cr157.00 Cr--187.16 Cr193.03 Cr-195.53 Cr223.95 Cr240.02 Cr
Cost of Revenue --------49.47 Cr55.63 Cr-47.20 Cr56.68 Cr62.16 Cr
Gross Profit --------137.69 Cr137.40 Cr-148.33 Cr167.27 Cr177.86 Cr
Operating Expenses 111.00 Cr100.00 Cr110.00 Cr103.00 Cr121.00 Cr115.00 Cr--93.76 Cr91.04 Cr-112.13 Cr106.21 Cr113.07 Cr
Operating Income 14.00 Cr25.00 Cr27.00 Cr19.00 Cr21.00 Cr31.00 Cr--43.93 Cr46.36 Cr-36.20 Cr61.06 Cr64.79 Cr
EBITDA 25.00 Cr35.00 Cr38.00 Cr32.00 Cr34.00 Cr42.00 Cr--61.66 Cr62.67 Cr-57.83 Cr79.98 Cr82.13 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr76.00 L60.00 L70.00 L78.00 L--1.52 Cr1.35 Cr
Pretax Income 17.00 Cr25.00 Cr28.00 Cr20.00 Cr23.00 Cr34.00 Cr--47.19 Cr50.48 Cr-35.39 Cr64.43 Cr68.29 Cr
Tax Provision 4.76 Cr7.75 Cr7.84 Cr5.20 Cr5.75 Cr9.86 Cr--25.62 Cr12.19 Cr-7.34 Cr15.73 Cr16.96 Cr
Net Income 12.00 Cr17.00 Cr20.00 Cr15.00 Cr17.00 Cr24.00 Cr--21.70 Cr38.93 Cr-29.01 Cr47.12 Cr52.19 Cr
Diluted EPS 0.791.091.280.971.121.52---2.403.011.812.983.22

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 183.00 Cr241.00 Cr304.00 Cr356.00 Cr403.00 Cr434.00 Cr495.00 Cr589.00 Cr517.20 Cr567.88 Cr680.71 Cr821.89 Cr
Cost of Revenue --------163.23 Cr166.70 Cr191.16 Cr219.57 Cr
Gross Profit --------353.97 Cr401.18 Cr489.55 Cr602.32 Cr
Operating Expenses 110.00 Cr147.00 Cr189.00 Cr212.00 Cr249.00 Cr261.00 Cr323.00 Cr353.00 Cr269.35 Cr308.47 Cr353.76 Cr397.67 Cr
Operating Income 60.00 Cr76.00 Cr97.00 Cr125.00 Cr128.00 Cr142.00 Cr141.00 Cr202.00 Cr84.62 Cr92.71 Cr135.79 Cr204.65 Cr
EBITDA 73.00 Cr94.00 Cr115.00 Cr145.00 Cr154.00 Cr174.00 Cr171.00 Cr236.00 Cr129.65 Cr147.19 Cr203.75 Cr274.26 Cr
Interest Expense 01.00 Cr001.00 Cr2.00 Cr1.00 Cr3.00 Cr2.35 Cr4.20 Cr3.05 Cr2.80 Cr
Pretax Income 68.00 Cr82.00 Cr82.00 Cr145.00 Cr138.00 Cr140.00 Cr152.00 Cr228.00 Cr88.59 Cr95.98 Cr145.44 Cr212.88 Cr
Tax Provision 23.80 Cr30.34 Cr39.36 Cr52.20 Cr52.44 Cr51.80 Cr39.52 Cr52.44 Cr24.23 Cr26.49 Cr54.69 Cr50.03 Cr
Net Income 44.00 Cr52.00 Cr43.00 Cr93.00 Cr85.00 Cr88.00 Cr113.00 Cr176.00 Cr64.49 Cr70.76 Cr91.51 Cr163.04 Cr
Diluted EPS 2.983.212.665.795.385.587.1311.104.054.455.7410.21

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 329.00 Cr410.00 Cr438.00 Cr479.00 Cr475.00 Cr469.00 Cr541.00 Cr-632.72 Cr643.88 Cr692.75 Cr747.22 Cr
Current Assets --------272.94 Cr278.51 Cr337.72 Cr372.29 Cr
Cash & Equivalents --------17.77 Cr9.30 Cr17.68 Cr38.32 Cr
Inventory --------27.67 Cr47.52 Cr46.54 Cr48.46 Cr
Receivables --------85.12 Cr43.47 Cr73.00 Cr73.88 Cr
Total Liabilities --------97.50 Cr116.25 Cr145.69 Cr161.20 Cr
Current Liabilities --------77.10 Cr90.48 Cr121.84 Cr109.91 Cr
Long Term Debt --------010.91 Cr0-
Total Debt 00002.00 Cr12.00 Cr8.00 Cr-23.31 Cr42.34 Cr24.68 Cr50.69 Cr
Total Equity 277.00 Cr366.00 Cr408.00 Cr444.00 Cr435.00 Cr367.00 Cr427.00 Cr-534.30 Cr526.77 Cr546.76 Cr585.50 Cr
Shares Outstanding --------15.88 Cr15.89 Cr15.90 Cr15.92 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 34.00 Cr68.00 Cr90.00 Cr107.00 Cr100.00 Cr168.00 Cr115.00 Cr-129.31 Cr167.63 Cr179.91 Cr213.24 Cr
Investing Cash Flow -18.00 Cr-18.00 Cr-42.00 Cr-43.00 Cr-12.00 Cr1.00 Cr-49.00 Cr--38.99 Cr-91.29 Cr-41.11 Cr-23.01 Cr
Financing Cash Flow -23.00 Cr-45.00 Cr-49.00 Cr-64.00 Cr-94.00 Cr-165.00 Cr-62.00 Cr--86.18 Cr-84.81 Cr-130.42 Cr-169.59 Cr
Capital Expenditure -9.00 Cr-15.00 Cr-37.00 Cr-44.00 Cr-39.00 Cr-10.00 Cr-22.00 Cr--43.65 Cr-61.58 Cr-33.48 Cr-20.88 Cr
Free Cash Flow 25.00 Cr53.00 Cr53.00 Cr63.00 Cr61.00 Cr158.00 Cr93.00 Cr-85.66 Cr106.05 Cr146.43 Cr192.36 Cr
Net Change in Cash -6.00 Cr5.00 Cr-0-0-5.00 Cr4.00 Cr4.00 Cr-4.14 Cr-8.47 Cr8.38 Cr20.64 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------68.4%70.6%71.9%73.3%
Operating Margin % 32.8%31.5%31.9%35.1%31.8%32.7%28.5%34.3%16.4%16.3%19.9%24.9%
Net Margin % 24.0%21.6%14.1%26.1%21.1%20.3%22.8%29.9%12.5%12.5%13.4%19.8%
ROE % 15.9%14.2%10.5%20.9%19.5%24.0%26.5%-12.1%13.4%16.7%27.8%
ROCE % --------15.2%16.8%23.8%32.1%

Shareholding Pattern

Insiders
51.18%
Institutions
20.20%
Public Float
41.38%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for THYROCARE

Google News hu, 13 Aug 2026

Thyrocare Technologies shares crash 8% as promoter offloads 9.9% stake - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVEdWM09LTk1ENnZyMk5lUFF0OGFRSUtYbXIwMkJQOTBpQTlCUzhBRGVtck9jM0x3ZFdUZjVLUWFnZkZPZGF1TWRaMWlnU3Y0c2p5OGFWbkN0LTV6RTRkUDRPYm5sT2pUTnEtbkd5WWZxT0lEdWJ6Rmpra0czbEtLc2xGT2JoLTFla1RFdm…

Google News Sun, 06 Sep 2026

API Holdings acquires 51% stake in Thyrocare via amalgamation scheme - scanx.trade

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPRUVtV2tJQkJ0cHdNZmpVLVNUYlQ1aGtfelZ1SFBDYjNNdW9icU04TEI3UVZTUHBIOUwzVm1lLTJsWG9mWG9xRHBiQ080WkhyX2IxOHUwcjA4X1N6Y1FBcUZsTVNrdW42bzN3bjNuX2QtNk1LMl9PVURuR3o1QVd5ODI5NGtORm0tb0paT2…

Google News Sun, 26 Jul 2026

Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQdlUyT0JkQk1zN2hYSTJIWk1kbDMxM3NkNktlV2dXVElYcmFmV09vOWJXcTEyVmhuS0hURUR5dDNIT19CQzBlYWdrNTkyRzZLR0VJN253VmdzcjFGSEhybnJnbjNraU11LUZBQWpmM1dOeElra1dmTTE3MW1FRE9Wc1pXUVZRN295UWhvQX…

Google News Fri, 14 Aug 2026

Thyrocare promoter Docon sells 9.9% stake for ₹986 crore; shares rise 3% - fortuneindia.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQVjlCb1Zxc2czWnNBRlhBWXJBanE0eFhNVlctQ0JlWl9hVER1cWR1T1JDbUd3VzdyQnJpbzdueEtzRWJUajlxck5JdGtiQ0hGNzk2bUtWT0hOZG5uVGljaE0tZVplSEhxaEhMa0xCcm03RnEwcXdTb3JOSkhsMDVNRHl2WC1xVXdmbFJJOV…

Google News ue, 18 Aug 2026

API Holdings Turns Debt-Free — Repays ₹1,050 Crore, Frees Thyrocare Shares from Pledge - The Tribune

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNU2otMWtDVC1vY2ZtMFlMNGQ3ck5TdVgwQ2JFbWF1V3BGQ3B3STdHUWtlUEZNdkoyOFNPdW53VXlKS3Y2S3ZFUHBDa2h6SVJubUx4ZjdtRnR3azlWQWZudUNXYnFROVVOUlJzSTNib2xPSHpZYmJYX0FTamJiS245LUhXbXpVR3o1SjZISF…

Google News Fri, 24 Jul 2026

Buy Thyrocare Technologies; target of Rs 650: ICICI Securities - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTzB4MENBUHliTnZZdHg4TGJxVVJENURKalZCRXJzVjJTT2dHcVAwTmxXUW9BLWNXRS1rRmdUTkc3MGsxYlpuckNETkNwTmxPVm5LTHhVYVphUjBvYkhTOG14TlU2WlFKRG51QkFSWTVtRzRGNzNOYjRFNzlhZzFFcGRRQnBPNkJpVzBIeF…

THYROCARE — Frequently Asked Questions

What is the current share price of Thyrocare Technologies Limited (THYROCARE)?

As of 2026-09-08 04:53 IST, Thyrocare Technologies Limited (THYROCARE) trades at ₹576.15 on NSE. Its 52-week range is ₹345.06 to ₹649.35.

What is the market capitalisation of THYROCARE?

Thyrocare Technologies Limited (THYROCARE) has a market capitalisation of ₹9,170.31 Cr on NSE.

What is the P/E ratio of THYROCARE?

THYROCARE trades at a trailing price-to-earnings (P/E) ratio of 56.41. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 16.40.

Does THYROCARE pay a dividend?

Thyrocare Technologies Limited (THYROCARE) currently offers a dividend yield of 2.73%.

What is the return on equity (ROE) of THYROCARE?

THYROCARE has a return on equity (ROE) of 27.85%. Its return on capital employed (ROCE) is 33.84%.

Is THYROCARE a good stock to buy?

This page provides a data-driven analysis of Thyrocare Technologies Limited (THYROCARE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space